UBS AM
ADVM

UBS AM’s Adverum Biotechnologies ADVM Stock Holding History

UBS AM’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-17,398
Closed -$378K – 2840
2021
Q3 		$378K Buy
17,398
+3,611
+26% +$92.2K ﹤0.01% 2578
2021
Q2 		$483K Sell
13,787
-44,340
-76% -$2.39M ﹤0.01% 2554
2021
Q1 		$5.73M Buy
58,127
+146
+0.3% +$17.5K ﹤0.01% 1282
2020
Q4 		$6.29M Sell
57,981
-26,069
-31% -$3.23M ﹤0.01% 1206
2020
Q3 		$8.66M Buy
84,050
+7,099
+9% +$1.06M ﹤0.01% 978
2020
Q2 		$16.1M Buy
76,951
+1,500
+2% +$266K 0.01% 794
2020
Q1 		$7.37M Buy
75,451
+49,061
+186% +$5.72M 0.01% 947
2019
Q4 		$3.04M Buy
+26,390
New +$2.33M ﹤0.01% 1413
2015
Q2 		– Sell
-590
Closed -$239K – 2695
2015
Q1 		$239K Buy
+590
New +$249K ﹤0.01% 2393
2014
Q4 		– Sell
-2,880
Closed -$985K – 2612
2014
Q3 		$985K Buy
+2,880
New +$857K ﹤0.01% 1571

Other funds holding ADVM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

UBS AM's ADVM Position: Q4 2021 in Review

UBS AM sold out of Adverum Biotechnologies (ADVM) in Q4 2021, closing a stake of 17,398 shares — an estimated $378K sold.

UBS AM first reported a position in ADVM in Q3 2014 and held it in 10 quarters. The position peaked at $16.1M in Q2 2020. 98 funds tracked by Wall St. Rank hold ADVM as of Q4 2021.

  • UBS AM reported no remaining Adverum Biotechnologies position as of Q4 2021 after selling out during the quarter.
  • UBS AM sold 17,398 Adverum Biotechnologies shares in Q4 2021, an estimated $378K.
  • UBS AM first reported a position in Adverum Biotechnologies in Q3 2014 and held it in 10 quarters.
  • UBS AM's Adverum Biotechnologies position peaked at $16.1M in Q2 2020.
  • 98 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2021.

Based on UBS AM's 13F filing for Q4 2021, filed 14 Feb 2022.